Posted by Michael Wonder on 11 Jul 2016
ICER to review treatments for rheumatoid arthritis and psoriatic arthritis
11 July 2016 - The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of new and emerging drug therapies for treatment of rheumatoid arthritis.
The report may also assess therapies for treatment of psoriatic arthritis (PsA); the decision of whether to include PsA will be made based on feedback received during the scoping period for the report.
Beginning with this review and effective for all future reviews, ICER will be instituting an "Open Input" period. This period begins immediately, with the announcement of the topic, and will last for three weeks. The Open Input period is intended to allow all stakeholders to share key information as ICER is developing the Draft Scoping Document. During this time, ICER will also be contacting key patient groups and clinical experts to gain further insights on the topic.
